AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06321796 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Antacid
Description: The antacid will be aluminum/magnesium hydroxide, 1x/day, 5 minutes before the MTP-101P. Each 5 ml consists of Aluminum Hydroxide - 200 mg, Magnesium Hydroxide - 200 mg, and Simethicone - 20 mg. If some participants cannot tolerate the aluminum/magnesium hydroxide, we will allow calcium carbonate alternatives equivalent in acid neutralizing capacity.~Duration: 12.5 weeks
Study NCT06321796 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Antacid
Description: The antacid will be aluminum/magnesium hydroxide, 1x/day, 5 minutes before the MTP-101P. Each 5 ml consists of Aluminum Hydroxide - 200 mg, Magnesium Hydroxide - 200 mg, and Simethicone - 20 mg. If some participants cannot tolerate the aluminum/magnesium hydroxide, we will allow calcium carbonate alternatives equivalent in acid neutralizing capacity.~Duration: 12.5 weeks
Study NCT06321796 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MTP-101P
Description: The same packaging will be used as for MTP-101P, but the sachets will contain a freeze-dried mixture of normal saline containing 10% Trehalose.~Duration: 12.5 weeks
Study NCT06321796 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vancomycin
Description: Same packaging and liquid carrier and flavoring used as for the oral vancomycin, but no vancomycin.~Duration: 10 days
Study NCT06144333 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: RIPH2
Description: * Blood sampling by capillary~* Swab sampling~* Blood sampling by venous punction~* Salivary sample, sputum, expectoration:
Study NCT05307432 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SPI+ Delivered by ED Staff
Description: ED staff will deliver SPI+ (Safety Planning Intervention plus follow-up phone calls) to patients at risk for suicide in the ED who are not admitted to an inpatient unit.
Study NCT04804943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NOA-001
Description: NOA-001 will be replaced regularly (at 22 to 24 hours after the initiation of procedure), and will be continuously performed until 168 hours from the enrollment.
Study NCT05307432 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPI+ Delivered by SPCC Clinicians
Description: The Suicide Prevention Consultation Center (SPCC) will be located external to the Emergency Department (ED). ED staff will be able to refer patients at risk for suicide to the SPCC. Licensed and credentialed mental health clinicians will deliver SPI+ (Safety Planning Intervention plus follow-up phone calls) via telehealth to patients at risk for suicide in the ED who are not admitted to an inpatient unit.
Study NCT06416293 — intervention group
Intervention type: OTHER
Intervention: Questionnaire patients
Description: Completion of a two-part questionnaire with a special focus on communication around the breast cancer diagnosis. Tumor stage and therapies received are also surveyed. The questionnaire can be answered online via a secure tool (REDCap) or in paper form.
Study NCT06416293 — intervention group
Intervention type: OTHER
Intervention: Questionnaire physicians
Description: Completion of a questionnaire with a special focus on communication around the breast cancer diagnosis
Study NCT05505526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: BL33 is located in the third posterior sacral foramen; BL35, 0.5 cun (≈10mm) lateral to the extremity of the coccyx; and SP6 posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus. BL33 will be inserted by needles of 0.30×75mm size at the angle of 45°, inward and downward, till the depth of 60-70mm. BL35 will be inserted by needles of 0.30×75mm size, slightly outward and upward, till the depth of 60-70mm. SP6 will be inserted by needles of 0.30×40mm till the depth of 25-30mm. All the needles will be lifted, thrust and twisted evenly for three times, right after insertion, to induce the sensation of deqi. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20 Hertz (Hz), electric current of 2-6.5 milliampere (mA) for BL33 and BL35, and 1mA-3.5mA for SP6.
Study NCT05505526 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham electroacupuncture
Description: Sham BL33 is in the area of 1 cun (≈20mm) horizontally outside BL33; sham BL35, 1 cun (≈20mm) horizontally outside BL35; Sham SP6, in the middle of SP6 and tendons. The three pairs of acupoints will be inserted by needles of 0.30×40mm size to a depth of 2-3mm till the needles can stand still. No manipulations will be conducted, and the sensation of deqi will not be induced. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20Hz and minimal electric current (ideally at a degree which participant can just percept). In about 30 seconds, the electric current will be turned down, leaving the indicator light and ticking sound on.
Study NCT05302622 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: There is no intervention planning
Description: There is no intervention planning
Study NCT05428813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: art therapy techniques
Description: Art therapy is a method that allows individuals to increase their self-awareness and realize their emotions better through artistic techniques.
Study NCT06399939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nap
Description: Naps are common but promoted by soothing, lying the infant down, and/or rocking and massaging
Study NCT06399939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wake
Description: Wake is encouraged by keeping the infant upright, providing stimulation (e.g., reading books, handing toys)
Study NCT06469931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: range of motion exercises
Description: In addition to range of motion exercises for wrist and hand and splinting, 3 sessions of ozone therapy will be applied once a week.
Study NCT06038162 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Parallel connection
Description: The RRT machine is connected on a separate vascular access (dialysis catheter).
Study NCT06038162 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Integrated connection
Description: A connection of the RRT machine with the input and output lines directly on the ECMO circuit.
Study NCT05029219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm I (Virtual reality group)
Description: In the preparatory session, the participant is given a survey. It is about demographic information such as gender, age, and age, as well as prior experience with the procedure. The primary test is performed with a fluoroscopy guided lumbar transforaminal epidural block with a human-shaped phantom.~After that, the test group and the control group receive the same audiovisual education for about 5 minutes. The test group receives about 60 minutes of training using a virtual reality program.
Study NCT06469931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy
Description: Patients in this group will receive ESWT once a week for 3 consecutive weeks in addition to range of motion exercises for wrist and hand and splinting.
Study NCT04915209 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Narrative interviews
Description: During the workshop, the participants will collectively create a common representation of the patient journey and co-design the envisioning care delivery model that support both social care and medical care.
Study NCT06469931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ozone therapy
Description: ozone therapy
Study NCT05029219 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arm II (Self study group)
Description: In the preparatory session, the participant is given a survey. It is about demographic information such as gender, age, and age, as well as prior experience with the procedure. The primary test is performed with a fluoroscopy guided lumbar transforaminal epidural block with a human-shaped phantom.~After that, the test group and the control group receive the same audiovisual education for about 5 minutes. The control group have provided with video materials and books provided during audiovisual education and have given time for self-study for 60 minutes. Subsequently, a second test is performed with a fluroscopy-guided lumbar transforaminal epidural block with a human-shaped phantom.
Study NCT05584748 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: tDCS is planned to be administered via electrodes positioned over the left dlPFC (anodal/sham electrode) and the left supraorbital area (reference electrode).
Study NCT05584748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: tDCS is planned to be administered via electrodes positioned over the left dlPFC (anodal/sham electrode) and the left supraorbital area (reference electrode).
Study NCT06172036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan liposome + oxaliplatin + 5-FU / LV
Description: Efficacy and safety of irinotecan liposome combined with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin calcium (LV) with or without adbellizumab for resectable pancreatic cancer
Study NCT06172036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan liposome + oxaliplatin + 5-FU / LV
Description: Efficacy and safety of irinotecan liposome combined with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin calcium (LV) with or without adbellizumab for resectable pancreatic cancer
Study NCT05860166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Scale
Description: Developing an Neurodevelopment Test for evaluating infants in their neonatal period.
Study NCT05080686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posthorax Thoraxbelt
Description: The patients will be assisted to put on the ThoraxBelt after surgery or at the emergency room by our research members and will be asked to keep it on except for showering through the whole study period.
Study NCT04152213 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Low GI diet
Description: This educational session will cover information on obesity, complications of obesity, the benefit of weight loss, the glycemic index and its associated low GI diet, a food-exchange table including high- to low-GI foods, and self-decision in food choices. The dietary advice will be based on the standard food pyramid for the conventional Chinese diet as promoted by the Hong Kong Department of Health, with an emphasis on the selection of low-GI products. Practical tips will be given such as the selection of low-GI rice and rice products, the impact of cooking methods (including cooking time, cooking conditions, and cooking liquid volume) on rice GI, intervention to reduce the GI of rice, and listing low-GI food options and meal plans.
Study NCT04152213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low GI diet
Description: This educational session will cover information on obesity, complications of obesity, the benefit of weight loss, the glycemic index and its associated low GI diet, a food-exchange table including high- to low-GI foods, and self-decision in food choices. The dietary advice will be based on the standard food pyramid for the conventional Chinese diet as promoted by the Hong Kong Department of Health, with an emphasis on the selection of low-GI products. Practical tips will be given such as the selection of low-GI rice and rice products, the impact of cooking methods (including cooking time, cooking conditions, and cooking liquid volume) on rice GI, intervention to reduce the GI of rice, and listing low-GI food options and meal plans.
Study NCT06507033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application and an arm volume measurement device
Description: The intervention consists mainly of two steps; (a) development of a mobile application with an arm volume measurement device (b) evaluation of the effectiveness of the products. Five components will be involved in the development of the mobile application. These components are; (I) exercise, (II) education, (III) coping mechanisms, (IV) arm volume measurement/recording and (V) appointment, exercise and measurement reminder panel. Exercise videos will include stretching exercises for the shoulder and arm as recommended in the guidelines
Study NCT05001672 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir alafenamide
Description: Tenofovir alafenamide (TAF, brand name: Vemlidy) is a hepatitis B virus nucleotide reverse transcriptase inhibitor oral medication for the treatment of chronic hepatitis B virus infection. It is a prodrug of tenofovir. Closely related to the commonly used reverse-transcriptase inhibitor tenofovir disoproxil fumarate, TAF has greater antiviral activity and better distribution into lymphoid tissues than that agent. Vemlidy was approved by the U.S. Food and Drug Administration (FDA) in November 2016 and the TAIWAN Food and Drug Administration (TFDA) in April 2017.
Study NCT05001672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide
Description: Tenofovir alafenamide (TAF, brand name: Vemlidy) is a hepatitis B virus nucleotide reverse transcriptase inhibitor oral medication for the treatment of chronic hepatitis B virus infection. It is a prodrug of tenofovir. Closely related to the commonly used reverse-transcriptase inhibitor tenofovir disoproxil fumarate, TAF has greater antiviral activity and better distribution into lymphoid tissues than that agent. Vemlidy was approved by the U.S. Food and Drug Administration (FDA) in November 2016 and the TAIWAN Food and Drug Administration (TFDA) in April 2017.
Study NCT05422027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Selinexor dose escalation: 40, 60mg respectively on day 1,8,15 for 21 days cycles
Study NCT05422027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: The investigators gave patients subcutaneous bortezomib 1.3mg/sqm on days 1, 8,15 of a 21- day cycle.~standard bortezomib-lenalidomide-dexamethasone
Study NCT05422027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: The investigators gave patients oral lenalidomide 25mg on days 1 to 14 of a 21-day cycle.~standard bortezomib-lenalidomide-dexamethasone
Study NCT05422027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: The investigators gave patients oral dexamethasone 40mg on days 1, 8, 15 of a 21-day cycle.~standard bortezomib-lenalidomide-dexamethasone
Study NCT05119140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 400mg of hydroxychloroquine per oral daily
Study NCT05119140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine
Description: the participant will maintain their current standard of care dose which can range from 1.5g to 4.8g of mesalamine per oral daily
Study NCT06069973 — intervention group
Intervention type: OTHER
Intervention: No intervention, observational study
Description: No intervention
Study NCT06172036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebellizumab
Description: Efficacy and safety of irinotecan liposome combined with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin calcium (LV) with or without adbellizumab for resectable pancreatic cancer
Study NCT05884567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercises
Description: These exercises are used to increase muscle endurance, power and ROM
Study NCT05884567 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization
Description: These exercises are used to increase ROM and used for pain reduction
Study NCT05642806 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks
Study NCT05642806 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks
Study NCT04891978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AIRQ
Description: A validated tool designed to identify patients who may be at risk for adverse outcomes from uncontrolled asthma.
Study NCT04891978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma Checklist
Description: A validated, 3-page tool, based on GINA and NAEPP guidelines to assist providers with recognition, evaluation, and optimization of all patients with asthma. In this study, healthcare providers will be required to complete the assess component (page 1) of the Asthma Checklist .
Study NCT04891978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRECISION Program (Educational Resources)
Description: Educational resources accessible to all providers in the study. There are provider-facing and patient-facing educational materials that can be accessed during the patient visit or as resources for before/after visits. Resources can be downloaded and sent to patients per the discretion of providers.
Study NCT05364515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRGF
Description: Plasma Rich in Growth Factors (PRGF) is a mixture of proteins and growth factors obtained from the blood of the patient.~Four PRGF infiltrations (two weeks between each infiltration). Then, application of topical PRGF serum (on alternate basis)
Study NCT05364515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol Propionate
Description: 0.05 propionate clobetasol: daily (first month), alternate (second moth), twice per week (from third month)
Study NCT05364515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Propionate
Description: 0.05 propionate clobetasol: daily (first month), alternate (second moth), twice per week (from third month)
Study NCT03941509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship
Description: Education, guidelines, communication tools and audit and feedback
Study NCT05474326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent pneumatic pressure device (Kendall SCD™ 700 Smart Compression™ System)
Description: application of intermittent pneumatic pressure device (Kendall SCD™ 700 Smart Compression™ System) on lower limbs and its effect on fetal and maternal doppler and amniotic fluid index in women with oligohydramnios. the compression system will be applicated on lower limbs for one hour in which it will produce intermittent compression on lower limbs. amniotic fluid amnout assessment will be done after this including doppler studies in order to detect any change in amniotic fluid amount or dopper.
Study NCT05818514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]AZ14132516
Description: Injection of radioligand for PET examinations
Study NCT06308250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIME THERAPY
Description: Mime therapy consist of:~Self massage: patients will be taught to massage their face and neck daily for about 10 minutes which includes effleurage and kneading of both sides of face.~Breathing exercises: patient will be taught to recognize tension and feel the difference between tension and relaxation in facial musculature for 5 minutes. Expiration exercises will be used to induce relaxation.~Articulation: vowels such as a,e,i,o,u and consonants such as p and b will be used to teach position of the lips for 5 minutes.~Facial expression exercises: forehead wrinkle, smiling, eye closure, frowning, disgust, surprise, anger, sadness will be performed for 10 minutes
Study NCT06308250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACTION OBSERVATION THERAPY
Description: Function of each of the muscle is observed for 3 minutes and then executed for 2 minutes.~Frontalis (Raising eyebrows and forehead wrinkling). Corrugator Supercili (Moving the eyebrow down and inward toward the nose and inner eye).~Orbicularis oculi (Closing the eyelids). Buccinator (Blowing air in and out of the mouth). Zygomaticus major (Smiling). Orbicularis oris (Lip pursing or puckering).
Study NCT06254976 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: 2 weeks of home exercise
Study NCT06254976 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: intraarticular knee PRP injections
Description: 2 doses of intra-articular platelet rich plasma (PRP) injection, 1 week apart
Study NCT06129981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imaginary exposure therapy augmented by vocal feedback
Description: The procedure specific to the study~* adding inclusion procedures (explanation of the study, verification of inclusion and non-inclusion criteria, signature of informed consent)~* including, in the usual initial V0 visit, psychometric measures specific to the study (RSDI, CGI, PMI, GEW)~* including a single usual psychotherapy session (i.e. not augmented) S1, during which the psychometric (RSDI, PMI, GEW) and psychophysiological (connected watch) measurements specific to the study are used~* adding the VF device and using psychometric (RSDI, PMI, GEW) and psychophysiological (connected watch) measurements specific to the study during psychotherapy sessions S2 to Sn (minimum S6)~* adding, during the last usual end-of-treatment visit, psychometric measures specific to the study (CGI)~* adding psychometric measures specific to the study during the usual follow-up visit at 3 months~* adding a follow-up visit at 12 months (CGI, PCL-5), either by telephone or on-site.